| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
88,975 |
80,666 |
$10.64M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
81,171 |
74,672 |
$10.02M |
| 80053 |
Comprehensive metabolic panel |
71,626 |
64,803 |
$1.14M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,460 |
3,186 |
$380K |
| 84484 |
|
17,561 |
13,785 |
$307K |
| 80320 |
|
3,215 |
2,719 |
$304K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,179 |
917 |
$244K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,212 |
1,108 |
$227K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
11,507 |
10,404 |
$222K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,134 |
1,071 |
$218K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
972 |
547 |
$142K |
| S9480 |
Intensive outpatient psychiatric services, per diem |
1,307 |
119 |
$134K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
998 |
897 |
$65K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
418 |
381 |
$64K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
944 |
851 |
$48K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
60,353 |
54,971 |
$46K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
385 |
344 |
$38K |
| 97597 |
|
755 |
477 |
$24K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
359 |
317 |
$14K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,537 |
848 |
$13K |
| 85027 |
|
95,261 |
85,779 |
$12K |
| 83690 |
|
29,041 |
26,486 |
$10K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
43 |
39 |
$9K |
| G0378 |
Hospital observation service, per hour |
45 |
27 |
$9K |
| 81001 |
|
14,327 |
13,176 |
$8K |
| 71045 |
Radiologic examination, chest; single view |
17,662 |
16,224 |
$8K |
| 84703 |
|
31,579 |
29,092 |
$8K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
4,264 |
4,050 |
$8K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
30,425 |
27,280 |
$7K |
| 80076 |
|
508 |
473 |
$7K |
| 70496 |
|
27 |
25 |
$7K |
| 93798 |
|
69 |
12 |
$6K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
57 |
57 |
$6K |
| 71046 |
Radiologic examination, chest; 2 views |
4,983 |
4,562 |
$5K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
19,361 |
17,575 |
$5K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
71 |
69 |
$4K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
185 |
28 |
$4K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
43 |
38 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
10,149 |
9,232 |
$2K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
12 |
12 |
$2K |
| 87634 |
|
33 |
29 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
938 |
850 |
$2K |
| 83880 |
|
238 |
222 |
$2K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
62 |
62 |
$2K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
17 |
15 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
17,569 |
13,029 |
$1K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
24 |
24 |
$1K |
| 97165 |
|
14 |
13 |
$884.18 |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
345 |
336 |
$834.90 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
175 |
159 |
$614.22 |
| 87430 |
|
449 |
434 |
$591.82 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
25 |
12 |
$555.22 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
173 |
136 |
$533.40 |
| 85379 |
|
66 |
65 |
$422.09 |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,087 |
975 |
$330.38 |
| J2060 |
Injection, lorazepam, 2 mg |
1,688 |
1,424 |
$315.96 |
| 81003 |
|
2,760 |
2,524 |
$315.86 |
| 82077 |
|
5,418 |
4,885 |
$261.75 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
342 |
331 |
$156.45 |
| 87428 |
|
319 |
309 |
$145.40 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
308 |
294 |
$59.35 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
694 |
650 |
$48.96 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
180 |
170 |
$45.15 |
| 36415 |
Collection of venous blood by venipuncture |
10,725 |
10,074 |
$31.11 |
| 83735 |
|
258 |
244 |
$29.17 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
103 |
99 |
$12.18 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,445 |
4,146 |
$9.60 |
| 82550 |
|
151 |
138 |
$6.51 |
| 87040 |
|
19 |
12 |
$6.09 |
| 82248 |
|
88 |
87 |
$4.14 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
344 |
326 |
$0.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,296 |
978 |
$0.00 |
| 85610 |
|
211 |
181 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
24 |
12 |
$0.00 |
| C9113 |
Injection, pantoprazole sodium, per vial |
14 |
13 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
59 |
56 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
43 |
38 |
$0.00 |
| 84702 |
|
12 |
12 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
13 |
13 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
248 |
186 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
45 |
37 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
98 |
94 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
47 |
39 |
$0.00 |
| 87081 |
|
33 |
33 |
$0.00 |
| 83605 |
|
13 |
12 |
$0.00 |
| 96376 |
|
14 |
13 |
$0.00 |
| 70498 |
|
14 |
13 |
$0.00 |